SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 323 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 4.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,779 | -4.0% | 66,516 | +22.2% | 0.00% | -25.0% |
| Q1 2024 | $1,854 | +47.8% | 54,441 | +25.4% | 0.00% | +33.3% |
| Q4 2023 | $1,254 | -1.5% | 43,422 | -6.0% | 0.00% | 0.0% |
| Q3 2023 | $1,273 | -11.0% | 46,171 | -2.8% | 0.00% | 0.0% |
| Q2 2023 | $1,430 | -23.7% | 47,525 | -8.3% | 0.00% | -40.0% |
| Q1 2023 | $1,875 | -4.7% | 51,803 | -6.1% | 0.01% | 0.0% |
| Q4 2022 | $1,967 | -99.9% | 55,175 | -7.2% | 0.01% | -16.7% |
| Q3 2022 | $2,013,000 | +31.7% | 59,471 | +12.4% | 0.01% | +50.0% |
| Q2 2022 | $1,529,000 | +0.7% | 52,889 | +15.3% | 0.00% | +33.3% |
| Q1 2022 | $1,519,000 | +14.4% | 45,859 | +0.6% | 0.00% | 0.0% |
| Q4 2021 | $1,328,000 | +9.1% | 45,570 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $1,217,000 | -12.7% | 45,266 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,394,000 | +15.4% | 45,266 | -1.9% | 0.00% | 0.0% |
| Q1 2021 | $1,208,000 | -7.9% | 46,122 | -11.5% | 0.00% | +50.0% |
| Q4 2020 | $1,311,000 | +7.5% | 52,120 | -11.0% | 0.00% | -33.3% |
| Q3 2020 | $1,220,000 | -20.7% | 58,552 | -9.6% | 0.00% | -25.0% |
| Q2 2020 | $1,538,000 | +22.4% | 64,768 | -7.6% | 0.00% | +33.3% |
| Q1 2020 | $1,257,000 | -15.5% | 70,087 | +10.7% | 0.00% | 0.0% |
| Q4 2019 | $1,488,000 | -35.6% | 63,288 | -9.5% | 0.00% | -40.0% |
| Q2 2019 | $2,309,000 | -6.0% | 69,919 | -0.4% | 0.01% | -28.6% |
| Q1 2019 | $2,456,000 | +17.5% | 70,165 | +2.9% | 0.01% | +16.7% |
| Q4 2018 | $2,091,000 | -35.7% | 68,165 | +5.5% | 0.01% | -25.0% |
| Q3 2018 | $3,254,000 | -18.6% | 64,626 | -3.3% | 0.01% | -11.1% |
| Q2 2018 | $3,997,000 | +30.7% | 66,843 | 0.0% | 0.01% | +28.6% |
| Q1 2018 | $3,058,000 | +14.7% | 66,843 | -0.2% | 0.01% | +16.7% |
| Q4 2017 | $2,666,000 | -1.1% | 66,983 | -2.4% | 0.01% | -14.3% |
| Q3 2017 | $2,695,000 | -14.0% | 68,659 | -5.7% | 0.01% | -12.5% |
| Q2 2017 | $3,134,000 | +42.1% | 72,814 | +3.1% | 0.01% | +33.3% |
| Q1 2017 | $2,206,000 | +34.6% | 70,594 | +8.8% | 0.01% | +20.0% |
| Q4 2016 | $1,639,000 | -50.1% | 64,865 | -51.2% | 0.01% | 0.0% |
| Q3 2016 | $3,282,000 | +251.0% | 132,848 | +189.3% | 0.01% | +66.7% |
| Q2 2016 | $935,000 | +1083.5% | 45,921 | +783.1% | 0.00% | – |
| Q1 2016 | $79,000 | +12.9% | 5,200 | 0.0% | 0.00% | – |
| Q4 2015 | $70,000 | -4.1% | 5,200 | 0.0% | 0.00% | – |
| Q3 2015 | $73,000 | – | 5,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |